WO2003032971A1 - 5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors - Google Patents
5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors Download PDFInfo
- Publication number
- WO2003032971A1 WO2003032971A1 PCT/EP2002/011576 EP0211576W WO03032971A1 WO 2003032971 A1 WO2003032971 A1 WO 2003032971A1 EP 0211576 W EP0211576 W EP 0211576W WO 03032971 A1 WO03032971 A1 WO 03032971A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- biphenyl
- amino
- cyclopropylmethyl
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Definitions
- This invention relates to novel compounds and their use as pharmaceuticals, particularly as p38 kinase inhibitors, for the treatment of certain diseases and conditions.
- R 1 when m is 0 to 4 R 1 is selected from C ⁇ alkyl, C 3 . cycloalkyl, C 2 . 6 alkenyl, -SO 2 NR 4 R 5 , -CONR 4 R 5 and -COOR 4 ; and when m is 2 to 4 R 1 is additionally selected from C ⁇ alkoxy, hydroxy, NR 4 R 5 , -NR 4 SO 2 R 5 , -NR 4 SOR 5 , -NR 4 COR 5 , and -NR 4 CONR 4 R 5 ;
- R 2 is selected from hydrogen, C ⁇ alkyl and -(CH 2 ) n -C 3 . 7 cycloalkyl;
- R 3 is the group -NH-CO-R 6 ;
- R 4 and R 5 are independently selected from hydrogen, C ⁇ . 6 alkyl, heterocyclyl optionally substituted by C M alkyl, and phenyl wherein the phenyl is optionally substituted by up to two groups independently selected from C ⁇ alkoxy, d-ealkyl and halogen; or R 4 and R 5 , together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic or heteroaryl ring optionally containing one additional heteroatom selected from oxygen, sulfur and nitrogen, wherein the ring may be substituted by up to two C ⁇ alkyl groups;
- R 6 is selected from hydrogen, C ⁇ alkyl, Ci-ealkoxy, -(CH 2 )p-C3- 7 cycloalkyl, trifluoromethyl, -(CH 2 ) q phenyl optionally substituted by R 7 and/or R 8 , -(CH 2 ) q heteroaryl optionally substituted by R 7 and/or R 8 ,
- R 7 cycloalkyl, -CONR 9 R 10 , - NHCOR 10 , -SO 2 NHR 9 , -NHSO 2 R 10 , halogen, -(CH 2 ) r NR 11 R 12 , oxy, trifluoromethyl, phenyl optionally substituted by one or more R 8 groups and heteroaryl wherein the heteroaryl may be optionally substituted by one or more R 8 groups;
- R 8 is selected from d-ealkyl, d-ealkoxy, halogen, trifluoromethyl and -NR 11 R 12 ; or R 7 and R 8 , together with the carbon atoms to which they are bound, form a five- or six-membered saturated or unsaturated ring to give a fused bicyclic ring system, wherein the ring that is formed by R 7 and R 8 may optionally contain one or two heteroatoms selected from oxygen, nitrogen and sulfur; R 9 is selected from hydrogen, d. 6 alkyl and phen
- R 10 is selected from hydrogen and C ⁇ . 6 alkyl; or R 9 and R 10 , together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R x , wherein the ring may be substituted by up to two d-ealkyl groups;
- R x is selected from hydrogen and methyl
- R 11 is selected from hydrogen, C h alky! and -(CH 2 ) p -C 3 _ 7 cycloalkyl optionally substituted by d-ealkyl
- R 12 is selected from hydrogen and C ⁇ - 6 alkyl
- R 11 and R 12 together with the nitrogen atom to which they are bound, form a three- to seven-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R x , wherein the ring may contain up to one double bond and the ring may be substituted by one or more R 13 groups;
- R 13 is selected from d-ealkyl, oxy, -CH 2 Od. 6 alkyl, trichloromethyl and -N(C 1 .
- U is selected from methyl and halogen
- W is selected from methyl and chlorine
- X and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1 , 2, 3 and 4 wherein each carbon atom of the resulting carbon chain may be optionally substituted with one or two groups selected independently from d. 6 alkyl optionally substituted by up to three halogens; n, p and q are independently selected from 0 and 1; r is selected from 0, 1 , 2 and 3; s is selected from 0, 1 and 2; or a pharmaceutically acceptable salt or solvate thereof.
- R 1 , R 2 , R 3 and m are as defined above, or a pharmaceutically acceptable salt or solvate thereof.
- the molecular weight of a compound of formula (I) does not exceed 1000, more preferably 800, even more preferably 600.
- R 1 is selected from d ⁇ alkyl, in particular, methyl or iso-propyl, C3_ 6 cycloalkyl, in particular cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl,
- R 1 is selected from C 3 . 6 cycloalkyl, in particular cyclopropyl; hydroxy; NR 4 R 5 , in particular -N(CH 3 ) 2 ; and -NR 4 SO 2 R 5 , in particular -
- R 2 is selected from hydrogen, d ⁇ alkyl and -CH 2 - cyclopropyl, more preferably hydrogen.
- R 4 and R 5 are independently selected from hydrogen, d. 4 alkyl and phenyl. Particularly preferred are hydrogen and methyl.
- R 6 is selected from -(CH 2 ) q phenyl optionally substituted by R 7 and/or R 8 and -(CH 2 ) q heteroaryl optionally substituted by R 7 and/or R 8 .
- R 6 is selected from d ⁇ alkyl, in particular methyl, ethyl, n-propyl or isobutyl; -(CH 2 ) p -C3-scycloalkyl, in particular cyclopropyl, -CH 2 - cyclopropyl, cyclobutyl or cyclopentyl; trifluoromethyl; -(CH 2 ) q phenyl optionally substituted by R 7 and/or R 8 ; -(CH 2 ) q heteroaryl optionally substituted by R 7 and/or R 8 , in particular furyl, -CH 2 -furyl, thienyl, thiazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl or pyrazinyl optionally substituted by R 7 and/or R 8 ; -(CH 2 ) q heterocyclyl optionally substituted by R 7 and/
- R 7 is selected from d ⁇ alkyl, halogen, -NR 11 R 12 , C 3 . ecycloalkyl, phenyl optionally substituted by one or more R 8 groups and heteroaryl optionally substituted by one or more R 8 groups.
- R 7 is selected from C ⁇ alkyl, in particular methyl or ethyl; d ⁇ alkoxy, in particular methoxy;
- R 8 is selected from C ⁇ . 2 alkyl and halogen.
- R 8 is selected from ⁇ alkyl, in particular methyl; halogen, in particular fluorine or chlorine; trifluoromethyl and -NR 11 R 12 .
- R 9 is selected from hydrogen and d ⁇ alkyl.
- R 10 is selected from hydrogen and d ⁇ alkyl.
- R 11 is selected from hydrogen, d ⁇ alkyl, C 3 - ecycloalkyl and -CH 2 C 3 . 6 cycloalkyl.
- R 11 is selected from hydrogen; d ⁇ alkyl, in particular methyl, ethyl or isobutyl; and -(CH 2 ) P -C 3 . 6 cycloalkyl in particular cyclopropyl, -CH 2 -cyclopropyl, cyclobutyl or cyclohexyl.
- R 12 is selected from hydrogen and d ⁇ alkyl.
- R 11 and R 12 together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R x , wherein R x is hydrogen or methyl, and the ring may be substituted by one or more R 13 groups.
- R 11 and R 12 together with the nitrogen atom to which they are bound, form a 1 ,2,3,6-tetrahydropyridyl.
- R 13 is selected from methyl and oxy.
- R 13 is selected from ⁇ alkyl, in particular methyl; oxy; -CH 2 Od- 4 alkyl, in particualr -CH 2 OCH 3 ; and -N(d- 6 alkyr) 2 , in particular -N(CH 3 ) 2 .
- W is methyl
- X and Y are each selected independently from hydrogen, chlorine and fluorine. In a further preferred embodiment, X is fluorine.
- m is selected from 0, 1 and 2, and when the carbon chain of m is substituted, these substituents are preferably one or two methyl and/or fluoro groups.
- m is selected from 0, 1 and 2 wherein each carbon atom of the resulting carbon chain may be optionally substituted with one or two groups selected independently from C h alky!.
- m is selected from 0, 1 , 2, 3 and 4, and when the carbon chain of m is substituted, these substituents are preferably one or two methyl groups.
- n is selected from 0, and 1.
- p is 0.
- q is 0.
- r is selected from 0, 1 and 2.
- s is selected from 0 and 1. In particular, s is 0.
- alkyl refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms.
- Ci-ealkyl means a straight or branched alkyl containing at least 1, and at most 6, carbon atoms.
- alkyl examples include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, isobutyl, isopropyl and t-butyl.
- a d ⁇ alkyl group is preferred, for example methyl, ethyl, or isopropyl.
- the said alkyl groups may be optionally substituted with one or more halogen atoms, in particular fluorine atoms, for example, trifluoromethyl.
- alkoxy refers to a straight or branched chain alkoxy group, for example, methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy, 2- methylprop-1-oxy, 2-methylprop-2-oxy, pentoxy, or hexyloxy.
- a d ⁇ alkoxy group is preferred, for example methoxy or ethoxy.
- cycloalkyl refers to a non-aromatic hydrocarbon ring containing the specified number of carbon atoms which may optionally contain up to one double bond.
- C 3 . 7 cycloalkyl means a non-aromatic ring containing at least three, and at most seven, ring carbon atoms.
- Examples of "cycloalkyl” as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- a C 3 . 6 cycloalkyl group is preferred, for example, cyclopropyl, cyclopentyl or cyclohexyl.
- R 1 is a C 3 . 7 cycloalkyl group
- the cycloalkyl group may be optionally substituted by one or more groups selected from Ci-ealkyl and phenyl, or the C3.
- 7 cycloalkyl group may be optionally substituted by two adjacent d-ealkyl groups, which together with the carbon atoms to which they are bound, form a fused bicyclic ring system.
- alkenyl refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms and containing at least one double bond.
- C 2 . 6 alkenyl means a straight or branched alkenyl containing at least 2, and at most 6, carbon atoms and containing at least one double bond.
- alkenyl as used herein include, but are not limited to ethenyl and propenyl.
- heteroaryl ring and “heteroaryl” refer to a monocyclic five- to seven-membered unsaturated hydrocarbon ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur.
- the heteroaryl ring has five or six ring atoms.
- heteroaryl rings include, but are not limited to, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl.
- the said ring may be optionally substituted by one or more substituents independently selected from d ⁇ alkyl and oxy.
- heterocyclic ring and “heterocyclyl” refer to a monocyclic three- to seven-membered saturated or non-aromatic, unsaturated hydrocarbon ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur.
- the heterocyclyl ring has five or six ring atoms.
- heterocyclyl groups include, but are not limited to, aziridinyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholino, tetrahydropyranyl, tetrahydrofuranyl, and thiomorpholino.
- the said ring may be optionally substituted by one or more substituents independently selected from d. 6 alkyl and oxy.
- fused bicyclic ring system and “fused bicyclyl” refer to a ring system comprising two five- to seven-membered saturated or unsaturated rings, the ring system optionally containing one or more heteroatoms independently selected from oxygen, nitrogen and sulfur. Preferably, each ring has five or six ring atoms.
- suitable fused bicyclic rings include, but are not limited to, naphthyl, indolyl, indolinyl, benzothienyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzodioxanyl, indanyl and tetrahydronaphthyl.
- Each ring may be optionally substituted with one or more substituents independently selected from halogen, d-ealkyl, oxy, -(CH 2 ) n NR 11 R 12 , - CO(CH 2 ) n NR 10 R 11 , and imidazolyl.
- substituents are chlorine, imidazolyl and -CH 2 -N(CH 3 ) 2 .
- halogen refers to the elements fluorine, chlorine, bromine and iodine. Preferred halogens are fluorine, chlorine and bromine. A particularly preferred halogen is fluorine or chlorine.
- the term "optionally” means that the subsequently described event(s) may or may not occur, and includes both event(s) which occur and events that do not occur.
- the term “substituted” refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.
- the term “solvate” refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a salt thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute.
- suitable solvents include water, methanol, ethanol and acetic acid.
- the solvent used is a pharmaceutically acceptable solvent.
- suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid. Most preferably the solvent used is water.
- Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms or may exhibit cis-trans isomerism).
- the individual stereoisomers (enantiomers and diastereomers) and mixtures of these are included within the scope of the present invention.
- the present invention also covers the individual isomers of the compounds represented by formula (I) as mixtures with isomers thereof in which one or more chiral centres are inverted.
- compounds of formula (I) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the present invention.
- Salts of the compounds of the present invention are also encompassed within the scope of the invention and may, for example, comprise acid addition salts resulting from reaction of an acid with a nitrogen atom present in a compound of formula (I). Salts encompassed within the term "pharmaceutically acceptable salts" refer to non- toxic salts of the compounds of this invention.
- Representative salts include the following salts: Acetate, Benzenesulfonate, Benzoate, Bicarbonate, Bisulfate, Bitartrate, Borate, Bromide, Calcium Edetate, Camsylate, Carbonate, Chloride, Clavulanate, Citrate, Dihydrochloride, Edetate, Edisylate, Estolate, Esylate, Fumarate, Gluceptate, Gluconate, Glutamate, Glycollylarsanilate, Hexylresorcinate, Hydrabamine, Hydrobromide, Hydrochloride, Hydroxynaphthoate, Iodide, Isethionate, Lactate, Lactobionate, Laurate, Malate, Maleate, Mandelate, Mesylate, Methylbromide, Methylnitrate, Methylsulfate, Monopotassium Maleate, Mucate, Napsylate, Nitrate, N- methylglucamine, Oxalate, Pamoate
- the compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working Examples.
- a general method (A) for preparing the compounds of Formula (I) comprises the reactions set out in Scheme 1 below.
- a general method (B) for preparing the compounds of Formula (I) comprises the reactions set out in Scheme 2 below.
- a general method (D) for preparing the compounds of Formula (I) comprises the reactions set out in Scheme 4 below.
- the acid compound (XII) may be converted to an activated form of the acid, for example the acid chloride, and then the activated acid thus formed reacted with the amine compound (XI)); or
- Suitable amide forming conditions are well known in the art and include treating a solution of the acid, in for example THF, with an amine in the presence of, for example, HATU and DIPEA.
- the compounds, salts or solvates of the present invention are conveniently administered in the form of pharmaceutical compositions.
- a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.
- the compounds of formula (I) and their pharmaceutically acceptable salts and solvates may be formulated for administration in any suitable manner. They may, for example, be formulated for topical administration or administration by inhalation or, more preferably, for oral, transdermal or parenteral administration.
- the pharmaceutical composition may be in a form such that it can effect controlled release of the compounds of formula (I) and their pharmaceutically acceptable salts and solvates.
- a particularly preferred method of administration, and corresponding formulation, is oral administration.
- the pharmaceutical composition may take the form of, and be administered as, for example, tablets (including sub-lingual tablets) and capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, emulsions, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.
- the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.
- a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.
- Capsules can be made by preparing a powder mixture as described above, and filling formed gelatin sheaths.
- Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation.
- a disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
- suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
- Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
- Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets.
- a powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate.
- a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone
- a solution retardant such as paraffin
- a resorption accelerator such as a quaternary salt
- an absorption agent such as bentonite, kaolin or dicalcium phosphate.
- the powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
- a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
- the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules.
- the granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil.
- the lubricated mixture is then compressed into tablets.
- the compounds of the present invention can also be combined with free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps.
- a clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided.
- Dyestuffs can be added to these coatings to distinguish different unit dosages.
- Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound.
- Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle.
- Suspensions can be formulated by dispersing the compound in a non-toxic vehicle.
- Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additives such as peppermint oil or saccharin, and the like can also be added.
- dosage unit formulations for oral administration can be microencapsulated.
- the formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.
- the compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
- Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
- the compounds of the present invention can also be administered in the form of liposome emulsion delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
- Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
- Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
- the compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
- Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues.
- the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- the present invention includes pharmaceutical compositions containing 0.1 to 99.5%, more particularly, 0.5 to 90% of a compound of the formula (I) in combination with a pharmaceutically acceptable carrier.
- composition may also be administered in nasal, ophthalmic, otic, rectal, topical, intravenous (both bolus and infusion), intraperitoneal, intraarticular, subcutaneous or intramuscular, inhalation or insufflation form, all using forms well known to those of ordinary skill in the pharmaceutical arts.
- the pharmaceutical composition may be given in the form of a transdermal patch, such as a transdermal iontophoretic patch.
- the pharmaceutical composition may be given as an injection or a continuous infusion (e.g. intravenously, intravasculariy or subcutaneously).
- the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- For administration by injection these may take the form of a unit dose presentation or as a multidose presentation preferably with an added preservative.
- the active ingredient may be in powder form for reconstitution with a suitable vehicle.
- the compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- the composition may be formulated for topical application, for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams.
- Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions.
- Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.
- the compounds according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropane, carbon dioxide or other suitable gas.
- a suitable propellant e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropane, carbon dioxide or other suitable gas.
- a suitable propellant e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropan
- compositions generally are administered in an amount effective for treatment or prophylaxis of a specific condition or conditions. Initial dosing in human is accompanied by clinical monitoring of symptoms, such symptoms for the selected condition.
- the compositions are administered in an amount of active agent of at least about 100 ⁇ g/kg body weight. In most cases they will be administered in one or more doses in an amount not in excess of about 20 mg/kg body weight per day. Preferably, in most cases, dose is from about 100 ⁇ g/kg to about 5 mg/kg body weight, daily.
- the daily dosage level of the active agent will be from 0. 1 mg/kg to 10 mg/kg and typically around 1 mg/kg.
- optimum dosage will be determined by standard methods for each treatment modality and indication, taking into account the indication, its severity, route of administration, complicating conditions and the like.
- the physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual.
- the effectiveness of a selected actual dose can readily be determined, for example, by measuring clinical symptoms or standard anti-inflammatory indicia after administration of the selected dose.
- the above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
- maintaining consistent daily levels in a subject over an extended period of time e.g., in a maintenance regime, can be particularly beneficial.
- the present invention provides a compound of formula (I) or a salt or solvate thereof, for use in therapy.
- the compounds of the present invention are generally inhibitors of the serine/threonine kinase p38 and are therefore also inhibitors of cytokine production which is mediated by p38 kinase.
- inhibitors of the serine/threonine kinase p38 are included those compounds that interfere with the ability of p38 to transfer a phosphate group from ATP to a protein substrate according to the assay described below.
- the compounds of the invention may be selective for one or more of the isoforms of p38, for example p38 ⁇ , p38 ⁇ , p38 ⁇ and/or p38 ⁇ .
- the compounds of the invention selectively inhibit the p38 ⁇ isoform.
- the compounds of the invention selectively inhibit the p38 ⁇ isoform.
- the compounds of the invention selectively inhibit the p38 ⁇ and p38 ⁇ isoforms.
- Assays for determining the selectivity of compounds for the p38 isoforms are described in, for example, WO 99/61426, WO 00/71535 and WO 02/46158.
- p38 kinase activity can be elevated (locally or throughout the body), p38 kinase can be incorrectly temporally active or expressed, p38 kinase can be expressed or active in an inappropriate location, p38 kinase can be constitutively expressed, or p38 kinase expression can be erratic; similarly, cytokine production mediated by p38 kinase activity can be occurring at inappropriate times, inappropriate locations, or it can occur at detrimentally high levels.
- the present invention also provides a method of inhibiting cytokine production which is mediated by p38 kinase activity in a subject, e.g. a human, which comprises administering to said subject in need of cytokine production inhibition a therapeutic, or cytokine-inhibiting, amount of a compound of the present invention.
- the compound may be administered as a single or polymorphic crystalline form or forms, an amorphous form, a single enantiomer, a racemic mixture, a single stereoisomer, a mixture of stereoisomers, a single diastereoisomer or a mixture of diastereoisomers.
- the present invention treats these conditions by providing a therapeutically effective amount of a compound of this invention.
- therapeutically effective amount is meant a symptom-alleviating or symptom-reducing amount, a cytokine-reducing amount, a cytokine-inhibiting amount, a kinase-regulating amount and/or a kinase- inhibiting amount of a compound.
- Such amounts can be readily determined by standard methods, such as by measuring cytokine levels or observing alleviation of clinical symptoms. For example, the clinician can monitor accepted measurement scores for anti-inflammatory treatments.
- the compounds of the present invention can be administered to any subject in need of inhibition or regulation of p38 kinase or in need of inhibition or regulation of p38 mediated cytokine production.
- the compounds may be administered to mammals.
- mammals can include, for example, horses, cows, sheep, pigs, mice, dogs, cats, primates such as chimpanzees, gorillas, rhesus monkeys, and, most preferably, humans.
- the present invention provides methods of treating or reducing symptoms in a human or animal subject suffering from, for example, rheumatoid arthritis, osteoarthritis, asthma, psoriasis, eczema, allergic rhinitis, allergic conjunctivitis, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, silicosis, endotoxemia, toxic shock syndrome, inflammatory bowel disease, tuberculosis, atherosclerosis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, multiple sclerosis, aneurism, stroke, irritable bowel syndrome, muscle degeneration, bone resorption diseases, osteoporosis, diabetes, reperfusion injury, graft vs.
- rheumatoid arthritis arthritis
- osteoarthritis asthma
- psoriasis eczema
- a further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, epilepsy and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
- a further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
- a further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease and epilepsy which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
- a further aspect of the invention provides a method of treatment of a human or animal subject suffering from any type of pain including chronic pain, rapid onset of analgesis, neuromuscular pain, headache, cancer pain, acute and chronic inflammatory pain associated with osteoarthritis and rheumatoid arthritis, post operative inflammatory pain, neuropathic pain, diabetic neuropathy, trigeminal neuralgia, post-hepatic neuralgia, inflammatory neuropathies and migraine pain which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
- a further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by p38 kinase activity.
- a further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, osteoarthritis, asthma, psoriasis, eczema, allergic rhinitis, allergic conjunctivitis, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, silicosis, endotoxemia, toxic shock syndrome, inflammatory bowel disease, tuberculosis, atherosclerosis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, multiple sclerosis, aneurism, stroke, irritable bowel syndrome, muscle degeneration, bone resorption diseases, osteoporosis, diabetes, reperfusion injury, graft vs.
- a condition or disease state selected from rheum
- a further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, epilepsy, and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer.
- a condition or disease state selected from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, epilepsy, and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer.
- a further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer.
- a condition or disease state selected from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer.
- a further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease and epilepsy.
- a further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of any type of pain including chronic pain, rapid onset of analgesis, neuromuscular pain, headache, cancer pain, acute and chronic inflammatory pain associated with osteoarthritis and rheumatoid arthritis, post operative inflammatory pain, neuropathic pain, diabetic neuropathy, trigeminal neuralgia, post-hepatic neuralgia, inflammatory neuropathies and migraine pain.
- Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one other pharmaceutically active agent.
- the compound(s) of formula (I) or pharmaceutically acceptable salt(s) or solvate(s) thereof and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately, this may occur separately or sequentially in any order.
- the amounts of the compound(s) of formula (I) or pharmaceutically acceptable salt(s) or solvate(s) thereof and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
- other pharmaceutically active agents which may be employed in combination with compounds of formula (I) and their salts and solvates for rheumatoid arthritis therapy include: immunosuppresants such as amtolmetin guacil, mizoribine and rimexolone; anti-TNF ⁇ agents such as etanercept, infliximab, diacerein; tyrosine kinase inhibitors such as leflunomide; kallikrein antagonists such as subreum; interleukin 11 agonists such as oprelvekin; interferon beta 1 agonists; hyaluronic acid agonists such as NRD-101
- Interleukin 1 receptor antagonists such as anakinra
- CD8 antagonists such as amiprilose hydrochloride
- beta amyloid precursor protein antagonists such as reumacon
- matrix metalloprotease inhibitors such as cipemastat and other disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate, sulphasalazine, cyclosporin A, hydroxychoroquine, auranofin, aurothioglucose, gold sodium thiomalate and penicillamine.
- DMARDs disease modifying anti-rheumatic drugs
- Carboxylic acid (0.4mmol), HATU (0.2mmol), DIPEA (105 ⁇ l), and amine (0.17mmol) were mixed in DMF (10ml) and heated for 18h at 80°C.
- the solvent was evaporated from the cooled reaction under vacuum and the residue was purified by SPE (silica, 10g) eluting with DCM and then DCM/ ethanol/ ammonia (300:8:1 to 100:8:1).
- the solvent was evaporated under vacuum from the product fractions which were further purified by SPE (C18, 5g), eluting with water, water/acetonitrile (1:1) and acetonitrile. Evaporation of the solvents under vacuum gave the amide.
- Example 1 N-(4'-(r(Cvclopropylmethyl)aminolcarbonyl)-6-methyl-1.1 '-biphenyl-3- vDnicotinamide a) N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3- yl)nicotinamide was prepared from 5'-amino-N-(cycIopropylmethyl)-2'-methyl-1,1'- biphenyl-4-carboxamide and nicotinic acid using method B.
- Methyl 5'-(t-butoxycarbonylamino)-2'-methyl-1 ,1 '-biphenyl-4-carboxylate (2.32g, 6.8mmol) and aqueous sodium hydroxide (2N, 7ml) were refluxed in methanol (40ml) for 12h. The solution was filtered through a celite pad and the filtrate concentrated to dryness under vacuum.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)-4- methylbenzamide was prepared from 5'-amino-N-(cyclopropylmethyl)-2'-methyl-1,1'- biphenyl-4-carboxamide and 4-methylbenzoic acid using method B.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 ,1 '-biphenyl-3-yl)-3-furamide was prepared from 5'-amino-N-(cyclopropylmethyl)-2'-methyl-1 ,1 '-biphenyl-4-carboxamide and 3-furoic acid using method B.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)-2-piperidin-1 - ylquinoline-4-carboxamide was prepared from 5'-amino-N-(cyclopropylmethyl)-2'- methyl-1,1'-biphenyl-4-carboxamide and 2-(piperidin-1-yl)quinoline-4-carboxylic acid using method B.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1,1'-biphenyl-3-yl)-2-pyrrolidin-1- ylisonicotinamide was prepared from 2-chloro-N-(4'-
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)-2-(4- methylpiperazin-1-yl)isonicotinamide was prepared from 2-chloro-N-(4'- ⁇ [(cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)isonicotinamide and N- methylpiperazine using method A.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)-2-piperidin-1 - ylisonicotinamide was prepared from 2-chioro-N-(4'-
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)-2- (isobutylamino)isonicotinamide was prepared from 2-chloro-N-(4'-
- Example 21 N-(4'-ff(Cyclopropylmethyl)aminolcarbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3- yl)-2-(3-dimethylaminopyrrolidin-1-yl)isonicotinamide
- Example 24 N-(4'-(r(Cvclopropylmethyl)aminolcarbonylV6-methyl-1 ⁇ '-biphenyl-3- yl)-2-(3.5-dimethylpiperidin-1-yl)isonicotinamide
- Example 25 N-(4'-f f (Cvclopropylmethyl)aminolcarbonyl)-6-methyl-1.1 '-biphenyl-3- yl)-2-(2-methoxymethylpyrrolidin-1-yl)isonicotinamide
- Example 27 N- ⁇ 4'-r(Cvclopropylamino)carbonvn-6-methyl-1.1 '-biphenyl-3-yl)-2- pyrrolidin-1 -ylisonicotinamide a) 2'-Methyl-5'-[(2-pyrrolidin-1-ylisonicotinoyl)amino]-1,1'-biphenyl-4-carboxylic acid
- Example 28 N-(4'-fr(Cvclopropylmethyl)aminolcarbonylV-6-methyl-1.1 '-biphenyl-3- yl)-5-(pyrid-2-yl)thiophene-2-carboxamide
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)-5-(pyrid-2- yl)thiophene-2-carboxamide was prepared from 5'-amino-N-(cyclopropyImethyl)-2'- methyl-1,1'-biphenyl-4-carboxamide and 5-(pyrid-2-yl)thiophene-2-carboxylic acid using method D. The product was further purified by preparative HPLC.
- Example 29 5-(4-Chlorophenyl)-N-(4'- ⁇ f(cvclopropylmethyl)aminolcarbonyl>-6- methyl-1 ⁇ '-biphenyl-3-yl)-2-furamide 5'-Amino-N-(cyclopropylmethyl)-2'-methyl-1 ,1'-biphenyl-4-carboxamide (53mg,
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)-2-(pyrid-3- yl)thiazole-4-carboxamide was prepared from 5'-amino-N-(cyclopropylmethyl)-2'-methyl- 1,1'-biphenyl-4-carboxamide and 2-(pyrid-3-yl)thiazole-4-carboxylic acid using method D.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)-4-methyl-2- (pyrid-3-yl)thiazole-5-carboxamide was prepared from 5'-amino-N-(cyclopropylmethyl)- 2'-methyl-1,1'-biphenyl-4-carboxamide and 4-methyl-2-(pyrid-3-yl)thiazole-5-carboxylic acid using method D.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)-1 -ethyl-3- (thiophen-2-yl)pyrazole-5-carboxamide was prepared from 5'-amino-N- (cyclopropylmethyl)-2'-methyl-1,1'-biphenyl-4-carboxamide and 1-ethyl-3-(thiophen-2- yl)pyrazole-5-carboxylic acid using method D.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl -1,1 '-biphenyl-3-yl)-2-(fur-2- yl)acetamide was prepared from 5'-amino-N-(cyclopropylmethyl)-2'-methyl-1,1'- biphenyl-4-carboxamide and fur-2-ylacetic acid using method D.
- DMSO 10.17,(1H, s), 8.61,(1H, t), 7.91,(2H, d), 7.55,(1H, m), 7.50-7.48,(2H, m), 7.40,(2H, d), 7.23,(1H, d), 6.38,(1 H, m), 6.25,(1H, d), 3.70,(2H, s), 3.16,(2H, t), 2.16,(3H, s), 1.04,(1 H, m), 0.42,(2H, m), 0.23,(2H, m).
- LCMS retention time 3.26min, MH + 389.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3- yl)cyclobutanecarboxamide was prepared from 5'-amino-N-(cyclopropylmethyl)-2'- methyl-1J'-biphenyl-4-carboxamide and cyclobutanecarboxylic acid using method D.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl) cyclopropanecarboxamide was prepared from 5'-amino-N-(cyclopropylmethyl)-2'- methyl-1,1'-biphenyl-4-carboxamide and cyclopropanecarboxylic acid using method D.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)-2-furamide was prepared from 5'-amino-N-(cyclopropylmethyl)-2'-methyl-1 ,1'-biphenyl-4-carboxamide and 2-furoic acid using method D.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)thiophene-3- carboxamide was prepared from 5'-amino-N-(cyclopropylmethyl)-2'-methyl-1,1'- biphenyl-4-carboxamide and 3-thiophene carboxylic acid using method D.
- Example 39 N-(4'- ⁇ f(Cvclopropylmethyl)aminolcarbonyl>-6-methyl-1J'-biphenyl-3- vDcvclopentanecarboxamide N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl -1 , 1 '-biphenyl-3- yl)cyclopentanecarboxamide was prepared from 5'-amino-N-(cyclopropylmethyl)-2'- methyl-1,1'-biphenyl-4-carboxamide and cyclopentanecarboxylic acid using method D.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1,1'-biphenyl-3-yl)tetrahydropyran- 4-carboxamide was prepared from 5'-amino-N-(cyclopropylmethyl)-2'-methyl-1 ,1'- biphenyl-4-carboxamide and tetrahydropyran-4-carboxylic acid using method D.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)tetrahydrofuran- 2-carboxamide was prepared from 5'-amino-N-(cyclopropylmethyl)-2'-methyl-1,1'- biphenyl-4-carboxamide and tetrahydrofuran-2-carboxylic acid using method D.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)thiazole-4- carboxamide was prepared from 5'-amino-N-(cyclopropylmethyl)-2'-methyl-1,1'- biphenyl-4-carboxamide and thiazole-4-carboxylic acid using method D.
- N-(4'- ⁇ [(Cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3-yl)isoxazole-5- carboxamide was prepared from 5'-amino-N-(cyclopropylmethyl)-2'-methyl-1,1'- biphenyl-4-carboxamide and isoxazole-5-carboxylic acid using method D.
- Example 47 5-Chloro-N-(4'-(r(cvclopropylmethyl)aminolcarbonyl)-6-methyl-1 A '- biphenyl-3-yl)-2-hexamethyleneiminopyrimidine-4-carboxamide 5'-Amino-N-(cyclopropylmethyl)-2'-methyl-1 , 1 '-biphenyl-4-carboxamide (53mg,
- Example 48 N-(4'-fr(Cvclopropylmethyl)aminolcarbonyl)-6-methyl-1.1 '-biphenyl-3- yl)-3-(2.5-dimethylpyrrol-1-yl)benzamide
- Example 52 N-(4'-(f (Cvclopropylmethyl)aminolcarbonyl)-6-methyl-1.1 '-biphenyl-3- yl)-3-fur-3-ylbenzamide 5'-Amino-N-(cyclopropylmethyl)-2'-methyl-1 , 1 '-biphenyl-4-carboxamide (48mg,
- Carbodiimde resin (442mg, O. ⁇ mmol) was added and shaking continued for 18h. The solution was filtered off, the resin washed with THF and methanol and the combined filtrate and washings reduced to dryness under vacuum. The residue was dissolved in ethyl acetate, washed with hydrochloric acid (1M) and aqueous sodium hydrogen carbonate. The solvent was evaporated from the organic fraction under vacuum to give 2-cyclopropyl-N-(4'- ⁇ [(cyclopropylmethyl)amino]carbonyl ⁇ -6-methyl-1 , 1 '-biphenyl-3- yl)quinoline-4-carboxamide.
- Example ⁇ 6 N-(4'- ⁇ r(Cvclopropylmethyl)aminolcarbonyl)-6-methyl-1 , 1 '-biphenyl-3- yl)-2-methyl-3-furamide ⁇ '-Amino-N-(cyclopropylmethyl)-2'-methyl-1 , 1 '-biphenyl-4-carboxamide (29mg,
- Example ⁇ 8 N-(4'-f r(Cyclopropylmethyl)aminolcarbonyl ⁇ -6-methyl-1.1 '-biphenyl-3- yDpropionamide ⁇ '-Amino-N-(cyclopropylmethyl)-2'-methyl-1 , 1 '-biphenyl-4-carboxamide (30mg, O.Hmmol) and propionic acid (18.5mg, 0.2 ⁇ mmol) were mixed in THF (3ml). Carbodiimde resin (295mg, 0.31 mmol) was added and shaking continued for 72h.
- Example 60 N-(4'-(r(CvclopropylmethvnaminolcarbonylV6-methyl-1.1'-biPhenyl-3- vDacetamide ⁇ '-Amino-N-(cyclopropylmethyl)-2'-methyl-1 , 1 '-biphenyl-4-carboxamide (30mg, O.Hmmol) and acetic acid (1 ⁇ .0mg, 0.2 ⁇ mmol) were mixed in THF (3ml). Carbodiimde resin (295mg, 0.31 mmol) was added and shaking continued for 72h.
- Example 61 N-(4'-fflCyclopropylmethyl)amino1carbonyl ⁇ -6-methyl-1.1 '-biphenyl-3- vDisovaleramide ⁇ '-Amino-N-(cyclopropylmethyl)-2'-methyl-1 , 1 '-biphenyl-4-carboxamide (30mg,
- Example 62 N-(4'-(f(Cvclopropylmethyl)aminolcarbonyl>-6-methyl-1J'-biphenyl-3- vDtrifluoroacetamide ⁇ '-Amino-N-(cyclopropylmethyl)-2'-methyl-1 , 1 '-biphenyl-4-carboxamide (30mg, O.Hmmol) and trifluoroacetic acid (28.5mg, 0.25mmol) were mixed in THF (3ml). Carbodiimde resin (29 ⁇ mg, 0.31 mmol) was added and shaking continued for 72h.
- Example 63 N-(4'-(r(Cvclopropylmethyl)amino1carbonyl)-6-methyl-1.1 '-biphenyl-3- yl)-6-(4-fluorophenyl)pyrazine-2-carboxamide ⁇ '-Amino-N-(cyclopropylmethyl)-2'-methyl-1 , 1 '-biphenyl-4-carboxamide (7 ⁇ mg,
- Example 64 N-(4'-(f(Cvclopropylmethyl)aminolcarbonyl)-6-methyl-1.1 '-biphenyl-3- yl)-6-morpholin-4-ylpyrazine-2-carboxamide ⁇ '-Amino-N-(cyclopropylmethyl)-2'-methyl-1 , 1 '-biphenyl-4-carboxamide (7 ⁇ mg,
- Example 65 N-(4'-(r(3-Dimethylaminopropyl)amino1carbonyl)-6-methyl-1.1 '- biphenyl-3-yl)-3-furamide a) ⁇ '-(3-Furoylamino)-2'-methyl-1,1'-biphenyl-4-carboxylic acid ( ⁇ Omg, OJ ⁇ mmol),
- Example 66 N-r6-Methyl-4'-((r2-(methylsulphonylamino)ethyllamino)carbonyl)-1.1 '- biphenyl-3-yll-3-furamide 5'-(3-Furoylamino)-2'-methyl-1,1'-biphenyl-4-carboxylic acid (30mg, 0.093mmol), N-(2- aminoethyl)methylsulphonamide (12.9mg, 0.093mmol), HATU (35.5mg, 0.093mmol), HOBT (12.6mg, 0.093mmol) and DIPEA (48 ⁇ l, 0.28mmol) in DMF (2ml) were stirred at room temperature for 18h.
- Example 67 N-(4'-
- Example 68 N-(4'-(r(3-Hvdroxypropyl)aminolcarbonyl)-6-methyl-1J'-biphenyl-3-yl)- 3-furamide 5'-(3-Furoylamino)-2'-methyl-1,1'-biphenyl-4-carboxylic acid (30mg, 0.093mmol), 3- hydroxypropylamine (7mg, 0.093mmol), HATU (35.5mg, 0.093mmol), HOBT (12.6mg, 0.093mmol) and DIPEA (4 ⁇ l, 0.2 ⁇ mmol) in DMF (2ml) were stirred at room temperature for 1 ⁇ h.
- Example 69 N-(4'- ⁇ f (Cvclopropylmethyl)aminolcarbonyl 6-methyl-1 , 1 '-biphenyl-3- yl)thiophene-2-carboxamide 5'-Amino-N-(cyclopropylmethyl)-2'-methyl-1 , 1 '-biphenyl-4-carboxamide (42mg,
- Example 70 N-(4'-f r(Cvclopropylmethyl)aminolcarbonylV-6-methyl-1.1 '-biphenyl-3- vPbenzamide
- Example 71 N-(4'-(f(Cvclopropylmethyl)aminolcarbonyl>-6-methyl-1J'-biphenyl-3- yl)- ⁇ -(3-chlorophenyl)-2-furamide ⁇ '-Amino-N-(cyclopropylmethyl)-2'-methyl-1 , 1 '-biphenyl-4-carboxamide (24mg,
- Example 72 N-(6-Chloro-4'-(f(cvclopropylmethyl)aminolcarbonyl>-1 J'-biphenyl-3- yl)-3-furamide N-(3-Bromo-4-chlorophenyl)-3-furamide (Intermediate 1, 63mg), N-cyclopropylmethyl-4-
- Example 75 N-(4'-(f(3-Hvdroxypropyl)aminolcarbonyl)-6-methyl-1J'-biphenyl-3- yl)thiophene-3-carboxamide
- Example 76 N-(4'-f f(2-Hvdroxyethyl)amino1carbonyl>-6-methyl-1.1 '-biphenyl-3- yl)thiophene-3-carboxamide
- Methyl (3'-amino-6'-methyl-1,r-biphen-4-yl)carboxylate (1.45g, 6.0mmol), thiophene-3- carboxylic acid (0.846g, 6.6mmol), HOBT (0.973g, 7.2mmol) and 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.38g, 7.2mmol) were dissolved in DMF (10ml). DIPEA (1.26ml, 7.2mmol) was added to the stirred solution, which was then stirred for 16 hours at 20°C. The solvent was removed in vacuo and the residue dissolved in ethyl acetate.
- the peptide substrate used in the p38 assay was biotin-IPTSPITTTYFFFRRR- amide.
- the p33 and MEK6 proteins were purified to homogeneity from E.coli expression systems.
- the fusion proteins were tagged at the N-terminus with Glutathione-S-Transferase (GST).
- the maximum activation was achieved by incubating 20uL of a reaction mixture of 30nM MEK6 protein and 120nM p38 protein in the presence of 1.5uM peptide and 10mM Mg(CH 3 CO 2 ) 2 in 100mM HEPES, pH 7.6, added to 1 ⁇ uL of a mixture of 1.5uM ATP with O.O ⁇ uCi [g- 33 P]ATP, with or without 1 ⁇ uL of inhibitor in 6%DMSO.
- the controls were reactions in the presence (negative controls) or absence (positive controls) of 50 mM EDTA.
- ⁇ P38 was prepared in house. SB4777790-R Ligand was diluted in HEPES containing MgCI 2 , CHAPS, DTT and DMSO. This was added to blank wells of a Black NUNC 384 well plate. ⁇ P38 was added to this ligand mixture then added to the remainder of the 384 well plate containing controls and compounds. The plates were read on an LJL Analyst and Fluorescence Anisotropy used to calculate the compound inhibition
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/492,605 US7432289B2 (en) | 2001-10-17 | 2002-10-16 | 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors |
EP02782931A EP1435934A1 (en) | 2001-10-17 | 2002-10-16 | 5'-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
AU2002346929A AU2002346929A1 (en) | 2001-10-17 | 2002-10-16 | 5-acylamino-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
JP2003535775A JP2005511531A (ja) | 2001-10-17 | 2002-10-16 | 5’−アシルアミノ−1,1’−ビフェニル−4−カルボキサミド誘導体およびp38キナーゼ阻害剤としてのそれらの使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0124939.0 | 2001-10-17 | ||
GBGB0124939.0A GB0124939D0 (en) | 2001-10-17 | 2001-10-17 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003032971A1 true WO2003032971A1 (en) | 2003-04-24 |
Family
ID=9924034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/011576 WO2003032971A1 (en) | 2001-10-17 | 2002-10-16 | 5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
Country Status (6)
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004004730A2 (en) * | 2002-07-06 | 2004-01-15 | Astex Technology Limited | 2-aminopyrazine derivatives as inhibitors of cyclin dependent kinases for the treatment of proliferative disorders |
WO2005012241A2 (en) * | 2003-07-25 | 2005-02-10 | Novartis Ag | p-38 KINASE INHIBITORS |
US7425555B2 (en) | 2002-04-30 | 2008-09-16 | Smithkline Beecham Corporation | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors |
US7652044B2 (en) | 2003-06-03 | 2010-01-26 | Novartis A.G. | P-38 inhibitors |
US7863314B2 (en) | 2003-06-26 | 2011-01-04 | Novartis Ag | 5-membered heterocycle-based p38 kinase inhibitors |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9365557B2 (en) | 2008-12-19 | 2016-06-14 | Vertex Pharmaceuticals Incorporated | Substituted pyrazin-2-amines as inhibitors of ATR kinase |
US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9791456B2 (en) | 2012-10-04 | 2017-10-17 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
US9862709B2 (en) | 2011-09-30 | 2018-01-09 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US10478430B2 (en) | 2012-04-05 | 2019-11-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
US10813929B2 (en) | 2011-09-30 | 2020-10-27 | Vertex Pharmaceuticals Incorporated | Treating cancer with ATR inhibitors |
US11291659B2 (en) | 2017-10-05 | 2022-04-05 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US11452713B2 (en) | 2016-02-29 | 2022-09-27 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods for treating low-proliferative disseminated tumor cells |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
EP1474395B1 (en) | 2002-02-12 | 2007-10-17 | Smithkline Beecham Corporation | Nicotinamide derivates useful as p38 inhibitors |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
GB0402140D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
GB0402138D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
GB0402137D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
GB0612026D0 (en) | 2006-06-16 | 2006-07-26 | Smithkline Beecham Corp | New use |
SG186229A1 (en) | 2010-06-07 | 2013-01-30 | Novomedix Llc | Furanyl compounds and the use thereof |
JP2017500333A (ja) * | 2013-12-20 | 2017-01-05 | バイエル・ファルマ・アクティエンゲゼルシャフト | グルコース輸送阻害剤 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0849256A1 (en) * | 1995-08-22 | 1998-06-24 | Japan Tobacco Inc. | Amide compounds and use of the same |
WO1999032463A1 (en) * | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
DE3919348A1 (de) | 1988-06-16 | 1989-12-21 | Ciba Geigy Ag | Mikrobizide mittel |
MX16687A (es) | 1988-07-07 | 1994-01-31 | Ciba Geigy Ag | Compuestos de biarilo y procedimiento para su preparacion. |
EP0430033A3 (en) | 1989-11-24 | 1991-09-11 | Ciba-Geigy Ag | Microbicidal agents |
EP0533268B1 (en) | 1991-09-18 | 2001-08-16 | Glaxo Group Limited | Benzanilide derivatives as 5-HT1D antagonists |
GB9119920D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
GB9816837D0 (en) | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
US5236934A (en) | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
GB2273930A (en) | 1992-12-30 | 1994-07-06 | Glaxo Group Ltd | Benzanilide derivatives |
TW240217B (US06894165-20050517-C00155.png) | 1992-12-30 | 1995-02-11 | Glaxo Group Ltd | |
IL108630A0 (en) | 1993-02-18 | 1994-05-30 | Fmc Corp | Insecticidal substituted 2,4-diaminoquinazolines |
GB2276161A (en) | 1993-03-17 | 1994-09-21 | Glaxo Group Ltd | Aniline and benzanilide derivatives |
GB2276162A (en) | 1993-03-17 | 1994-09-21 | Glaxo Group Ltd | Aniline and benazilide derivatives |
JP2860603B2 (ja) | 1993-08-31 | 1999-02-24 | ファイザー・インク. | 5−アリールインドール誘導体 |
WO1995006644A1 (en) | 1993-09-03 | 1995-03-09 | Smithkline Beecham Plc | Amide derivatives as 5ht1d receptor antagonists |
WO1995011243A1 (en) | 1993-10-19 | 1995-04-27 | Smithkline Beecham Plc | Benzanilide derivatives as 5ht-1d receptor antagonists |
AU1108395A (en) | 1993-12-07 | 1995-06-27 | Smithkline Beecham Plc | Heterocyclic biphenylylamides useful as 5ht1d antagonists |
GB9326008D0 (en) | 1993-12-21 | 1994-02-23 | Smithkline Beecham Plc | Novel compounds |
GB9408577D0 (en) | 1994-04-29 | 1994-06-22 | Fujisawa Pharmaceutical Co | New compound |
EP0758330A1 (en) | 1994-05-06 | 1997-02-19 | Smithkline Beecham Plc | Biphenylcarboxamides useful as 5-ht1d antagonists |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
HUP9801602A3 (en) | 1995-04-04 | 1999-01-28 | Glaxo Group Ltd | Imidazo[1,2-a]pyridine derivatives, process for their production, pharmaceutical compositions and use thereof |
GB9507203D0 (en) | 1995-04-07 | 1995-05-31 | Smithkline Beecham Plc | Novel compounds |
IL118544A (en) | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
AU709961B2 (en) | 1995-07-10 | 1999-09-09 | Dow Chemical Company, The | Polynitrile oxides |
US6080767A (en) | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
US6323227B1 (en) | 1996-01-02 | 2001-11-27 | Aventis Pharmaceuticals Products Inc. | Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
US5756499A (en) | 1996-01-11 | 1998-05-26 | Smithkline Beecham Corporation | Substituted imidazole compounds |
FR2754260B1 (fr) | 1996-10-04 | 1998-10-30 | Adir | Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US5945418A (en) | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US6087496A (en) | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
RU2249591C2 (ru) | 1997-05-22 | 2005-04-10 | Дж.Д. Серл Энд Ко. | 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38 |
US20020156104A1 (en) | 1997-06-13 | 2002-10-24 | Jerry L. Adams | Novel pyrazole and pyrazoline substituted compounds |
CA2293824A1 (en) | 1997-06-19 | 1998-12-23 | Mimi Lifen Quan | (amidino)6-membered aromatics as factor xa inhibitors |
US6060491A (en) | 1997-06-19 | 2000-05-09 | Dupont Pharmaceuticals | 6-membered aromatics as factor Xa inhibitors |
WO1999001452A1 (en) | 1997-07-02 | 1999-01-14 | Smithkline Beecham Corporation | Novel cycloalkyl substituted imidazoles |
DE69833464T2 (de) | 1997-09-05 | 2006-08-24 | Glaxo Group Ltd., Greenford | Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate |
JPH11218884A (ja) | 1998-02-03 | 1999-08-10 | Konica Corp | ハロゲン化銀写真感光材料 |
DE19817461A1 (de) | 1998-04-20 | 1999-10-21 | Basf Ag | Neue substituierte Benzamide, deren Herstellung und Anwendung |
CN1185211C (zh) | 1998-05-15 | 2005-01-19 | 阿斯特拉曾尼卡有限公司 | 用于治疗由细胞活素引起的疾病的苯甲酰胺衍生物 |
US6867209B1 (en) | 1998-05-22 | 2005-03-15 | Scios, Inc. | Indole-type derivatives as inhibitors of p38 kinase |
US6448257B1 (en) | 1998-05-22 | 2002-09-10 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
US6130235A (en) | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
CA2342251A1 (en) | 1998-08-28 | 2000-03-09 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
JP2002526482A (ja) | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | p38のインヒビター |
KR20010075673A (ko) | 1998-11-03 | 2001-08-09 | 그레이엄 브레레톤, 레슬리 에드워즈 | 선택적 cox-2 억제제로서의 피라졸로피리딘 유도체 |
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US6545054B1 (en) | 1999-02-11 | 2003-04-08 | Millennium Pharmaceuticals, Inc. | Alkenyl and alkynyl compounds as inhibitors of factor Xa |
US6498166B1 (en) | 1999-02-27 | 2002-12-24 | Smithkline Beecham Corporation | Pyrazolopyridines |
GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
US6509361B1 (en) | 1999-05-12 | 2003-01-21 | Pharmacia Corporation | 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors |
WO2000071510A2 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
EP1189879A1 (en) | 1999-05-24 | 2002-03-27 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
JP2003500376A (ja) | 1999-05-24 | 2003-01-07 | シーオーアール セラピューティクス インコーポレイテッド | Xa因子の阻害剤 |
DE19932571A1 (de) | 1999-07-13 | 2001-01-18 | Clariant Gmbh | Verfahren zur Herstellung von Biarylen unter Palladophosphacyclobutan-Katalyse |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
US6576632B1 (en) | 1999-08-27 | 2003-06-10 | Pfizer Inc | Biaryl compounds useful as anticancer agents |
GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
AU784484B2 (en) | 1999-11-10 | 2006-04-13 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted 2-aryl-3(heteroaryl)-imidazo(1,2-a) pyrimidines, and related pharmaceutical compositions and methods |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
DE10059418A1 (de) | 2000-11-30 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
DE10060807A1 (de) | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
DE10063008A1 (de) | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
MXPA03008144A (es) | 2001-03-09 | 2003-12-12 | Pfizer Prod Inc | Nuevos compuestos antiinflamatorios de triazolopiridinas. |
RU2003132706A (ru) | 2001-04-06 | 2005-04-20 | Байокрист Фармасьютикалз, Инк. (Us) | Диариловые соединения в качестве ингибиторов сериновых протеаз |
AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
GB0124848D0 (en) | 2001-10-16 | 2001-12-05 | Celltech R&D Ltd | Chemical compounds |
GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124934D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124932D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124936D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
EP1474395B1 (en) | 2002-02-12 | 2007-10-17 | Smithkline Beecham Corporation | Nicotinamide derivates useful as p38 inhibitors |
US20030225089A1 (en) | 2002-04-10 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
US20040116479A1 (en) | 2002-10-04 | 2004-06-17 | Fortuna Haviv | Method of inhibiting angiogenesis |
US7136850B2 (en) | 2002-12-20 | 2006-11-14 | International Business Machines Corporation | Self tuning database retrieval optimization using regression functions |
GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
BRPI0412918A (pt) | 2003-07-25 | 2006-09-26 | Novartis Ag | inibidores de quinases p38 |
-
2001
- 2001-10-17 GB GBGB0124939.0A patent/GB0124939D0/en not_active Ceased
-
2002
- 2002-10-16 EP EP02782931A patent/EP1435934A1/en not_active Withdrawn
- 2002-10-16 JP JP2003535775A patent/JP2005511531A/ja active Pending
- 2002-10-16 US US10/492,605 patent/US7432289B2/en not_active Expired - Fee Related
- 2002-10-16 AU AU2002346929A patent/AU2002346929A1/en not_active Abandoned
- 2002-10-16 WO PCT/EP2002/011576 patent/WO2003032971A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0849256A1 (en) * | 1995-08-22 | 1998-06-24 | Japan Tobacco Inc. | Amide compounds and use of the same |
WO1999032463A1 (en) * | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7425555B2 (en) | 2002-04-30 | 2008-09-16 | Smithkline Beecham Corporation | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors |
WO2004004730A3 (en) * | 2002-07-06 | 2004-04-29 | Astex Technology Ltd | 2-aminopyrazine derivatives as inhibitors of cyclin dependent kinases for the treatment of proliferative disorders |
WO2004004730A2 (en) * | 2002-07-06 | 2004-01-15 | Astex Technology Limited | 2-aminopyrazine derivatives as inhibitors of cyclin dependent kinases for the treatment of proliferative disorders |
US7652044B2 (en) | 2003-06-03 | 2010-01-26 | Novartis A.G. | P-38 inhibitors |
US8410160B2 (en) | 2003-06-26 | 2013-04-02 | Novartis Ag | 5-membered heterocycle-based P38 kinase inhibitors |
US7863314B2 (en) | 2003-06-26 | 2011-01-04 | Novartis Ag | 5-membered heterocycle-based p38 kinase inhibitors |
US8580838B2 (en) | 2003-06-26 | 2013-11-12 | Novartis Ag | 5-membered heterocycle-based p38 kinase inhibitors |
US8242117B2 (en) | 2003-06-26 | 2012-08-14 | Novartis Ag | 5-membered heterocycle-based p38 kinase inhibitors |
EP2298743A1 (en) | 2003-06-26 | 2011-03-23 | Novartis AG | 5-membered heterocycle-based P38 kinase inhibitors |
US7754726B2 (en) | 2003-07-25 | 2010-07-13 | Novartis Ag | Benzamide derivatives as p-38 kinase inhibitors |
EP1990338A2 (en) | 2003-07-25 | 2008-11-12 | Novartis AG | Biphenylcyclopropylamides as p-38 Kinase inhibitors |
US7700622B2 (en) | 2003-07-25 | 2010-04-20 | Novartis Ag | p-38 kinase inhibitors |
WO2005012241A3 (en) * | 2003-07-25 | 2005-04-14 | Triad Therapeutics Inc | p-38 KINASE INHIBITORS |
WO2005012241A2 (en) * | 2003-07-25 | 2005-02-10 | Novartis Ag | p-38 KINASE INHIBITORS |
US10479784B2 (en) | 2008-12-19 | 2019-11-19 | Vertex Pharmaceuticals Incorporated | Substituted pyrazin-2-amines as inhibitors of ATR kinase |
US10961232B2 (en) | 2008-12-19 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Substituted pyrazines as ATR kinase inhibitors |
US9365557B2 (en) | 2008-12-19 | 2016-06-14 | Vertex Pharmaceuticals Incorporated | Substituted pyrazin-2-amines as inhibitors of ATR kinase |
US9701674B2 (en) | 2008-12-19 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Substituted pyrazines as ATR kinase inhibitors |
US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10813929B2 (en) | 2011-09-30 | 2020-10-27 | Vertex Pharmaceuticals Incorporated | Treating cancer with ATR inhibitors |
US10208027B2 (en) | 2011-09-30 | 2019-02-19 | Vertex Pharmaceuticals Incorporated | Processes for preparing ATR inhibitors |
US9862709B2 (en) | 2011-09-30 | 2018-01-09 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
US10822331B2 (en) | 2011-09-30 | 2020-11-03 | Vertex Pharmaceuticals Incorporated | Processes for preparing ATR inhibitors |
US10478430B2 (en) | 2012-04-05 | 2019-11-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
US11110086B2 (en) | 2012-04-05 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
US9791456B2 (en) | 2012-10-04 | 2017-10-17 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
US11452713B2 (en) | 2016-02-29 | 2022-09-27 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods for treating low-proliferative disseminated tumor cells |
US10537560B2 (en) | 2017-10-05 | 2020-01-21 | Fulcrum Therapeutics. Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US11291659B2 (en) | 2017-10-05 | 2022-04-05 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US11479770B2 (en) | 2017-10-05 | 2022-10-25 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of DUX4 |
Also Published As
Publication number | Publication date |
---|---|
US7432289B2 (en) | 2008-10-07 |
AU2002346929A1 (en) | 2003-04-28 |
US20040242868A1 (en) | 2004-12-02 |
JP2005511531A (ja) | 2005-04-28 |
GB0124939D0 (en) | 2001-12-05 |
EP1435934A1 (en) | 2004-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003032971A1 (en) | 5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | |
EP1474395B1 (en) | Nicotinamide derivates useful as p38 inhibitors | |
EP1436272B1 (en) | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | |
US7208629B2 (en) | 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | |
EP1448513A1 (en) | Biphenyl-derivatives as p38-kinase inhibitors | |
US7396843B2 (en) | 5′-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | |
WO2003032987A1 (en) | 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | |
WO2003032970A1 (en) | 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | |
WO2003033482A1 (en) | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | |
WO2004010995A1 (en) | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis | |
EP1435949A1 (en) | 2' -methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003535775 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10492605 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002782931 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002782931 Country of ref document: EP |